skip to Main Content

South San Francisco, CA, June 18, 2019 – FlemingMartin is pleased to announce that MyoKardia (NASDAQ: MYOK), a biopharmaceutical company pioneering a precision approach to serious, neglected, and rare cardiovascular diseases, has hired John Cross as Vice President of Total Rewards.

Mr. Cross brings deep total rewards expertise to MyoKardia, having strategically developed Global Compensation and Benefits, Executive and Board Compensation, and Equity Programs at numerous publicly-traded life sciences and technology companies. Most recently, Mr. Cross served in-house as Head of Global Total Rewards for Intuitive Surgical (NASDAQ: ISRG). Mr. Cross holds dual MBA and MLIR degrees from Cornell University along with a Bachelors in Finance from Washington State University.


MYOK new logo

MyoKardia (NASDAQ: MYOK) is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.


Fleming Martin Color Logo Large 72 ppi FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs of companies to build successful execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.

Back To Top